Zhen Lu

Mid-cap, biotech, macro, long only
Zhen Lu
Mid-cap, biotech, macro, long only
Contributor since: 2013
Pandora: Poised For Profit?
BBRY Has A Couple More Aces In The Hole
Groupon: Deal's Not Over Yet
Netflix: The Video On Demand Battle
Opko Health's Plate Is Too Full
Affymax Revisited
Google: Too Big To Fall?
Ulta: Buy In Before It's Too Late
Ziopharm: What Happens Next?
Facebook: Is It Capable Of More Revenue?
Affymax: A Binary Play
Zynga: Here For The Long Game
BlackBerry: The New Fruit In Town
Keryx Pharmaceuticals: In Or Out?